FDA PreCheck Pilot Program to Build Manufacturing Readiness
The FDA PreCheck Pilot Program aims to strengthen U.S. domestic drug manufacturing through regulatory engagement, manufacturing readiness, and advanced production.
Articles, expert interviews, and insights from life sciences leaders
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
AI and Neuroscience. Why Big Pharma Is Betting on the Brain
AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.
FDA Master Protocol Guidance for Smarter Clinical Trials
Explore the FDA's Master Protocol guidance and how basket, umbrella, and platform trials can improve clinical trial efficiency, especially in oncology and biologics.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Operation TrialBlazer: Can the U.S. Reclaim Clinical Trial Leadership?
Operation TrialBlazer aims to reignite U.S. clinical development by accelerating trials, modernising FDA oversight, and strengthening pharmaceutical innovation.
Genomic Governance Ensures Equity at the Core of Drug Discovery
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
FDA Registration for Drug Manufacturing Enters a New Era
The FDA's proposed drug manufacturing modernisation rule could accelerate distributed manufacturing, digital quality systems, and pharma supply chain resilience.
AAV Vector Manufacturing: Solving Gene Therapy's Bottleneck
Discover how innovations in AAV vector manufacturing are improving scalability, quality, and commercial readiness for next-generation gene therapies.
11 Clinical Trials Defining Pharmaceutical Strategy in 2026
We've mapped the competitive, regulatory, and commercial stakes of the top 11 clinical trials that have defined pharma strategy so far in 2026.
Anthropic’s Big AI Drug Discovery Announcement
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
How AI Is Reshaping Data Integrity in Pharma Manufacturing
Veragence CEO Nour AlSaleh discusses how AI is transforming data integrity in pharma manufacturing, regulatory compliance, the "human-in-the-loop" requirement, and patient safety in the era of AI-driven GxP systems.
Digital Measures in Clinical Trials: FDA vs EMA Pathways
Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.
